King Pharmaceuticals KG Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's cash & equivalents?
- King Pharmaceuticals (KG) reported cash & equivalents of $62.21M in Q1 2026.
- How has King Pharmaceuticals's cash & equivalents changed year-over-year?
- King Pharmaceuticals's cash & equivalents increased by 1724.4% year-over-year, from $3.41M to $62.21M.
- What is the long-term trend for King Pharmaceuticals's cash & equivalents?
- Over 2 years (2023 to 2025), King Pharmaceuticals's cash & equivalents has grown at a 110.6% compound annual growth rate (CAGR), from $5.55M to $24.63M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.